|This article needs additional citations for verification. (December 2007)|
|Subdivisions||Medical oncology, radiation oncology, surgical oncology|
|Significant tests||Tumor markers, TNM staging, CT scans, MRI|
Oncology is a branch of medicine that deals with tumors. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word onkos (όγκος), meaning "tumor", "volume" or "mass".
Oncology is concerned with:
- The diagnosis of any cancer in a person (pathology)
- Therapy (e.g. surgery, chemotherapy, radiotherapy and other modalities)
- Follow-up of cancer patients after successful treatment
- Palliative care of patients with terminal malignancies
- Ethical questions surrounding cancer care
- Screening efforts:
- of populations, or
- of the relatives of patients (in types of cancer that are thought to have a hereditary basis, such as breast cancer)
Medical histories remain an important screening tool: the character of the complaints and nonspecific symptoms (such as fatigue, weight loss, unexplained anemia, fever of unknown origin, paraneoplastic phenomena and other signs) may warrant further investigation for malignancy. Occasionally, a physical examination may find the location of a malignancy.
Diagnostic methods include:
- Biopsy or Resection; these are methods by which suspicious neoplastic growths can be removed in part or in whole, and evaluated by a pathologist to determine malignancy. This is currently the gold standard for the diagnosis of cancer and is crucial in guiding the next step in management (active surveillance, surgery, radiation therapy, chemotherapy or a combination of these)
- Endoscopy, either upper or lower gastrointestinal, cystoscopy, bronchoscopy, or nasendoscopy; to localise areas suspicious for malignancy and biopsy when necessary.
- X-rays, CT scanning, MRI scanning, ultrasound and other radiological techniques to localise and guide biopsy.
- Scintigraphy, Single Photon Emission Computed Tomography (SPECT), Positron emission tomography (PET) and other methods of nuclear medicine to identify areas suspicious for malignancy.
- Blood tests, including tumor markers, which can increase the suspicion of certain types of cancers.
Currently, a tissue diagnosis (from a biopsy) by a pathologist is essential for the proper classification of cancer and to guide the next step of treatment. On extremely rare instances when this is not possible, "empirical therapy" (without an exact diagnosis) may be considered, based on the available evidence (e.g. history, x-rays and scans.)
On very rare occasions, a metastatic lump or pathological lymph node is found (typically in the neck) for which a primary tumor cannot be found. However, immunohistochemical markers often give a strong indication of the primary malignancy. This situation is referred to as "malignacy of unknown primary", and again, treatment is empirical based on past experience of the most likely origin.
Depending upon the cancer identified, followup and palliative care will be administered at that time. Certain disorders (such as ALL or AML) will require immediate admission and chemotherapy, while others will be followed up with regular physical examination and blood tests.
Often, surgery is attempted to remove a tumor entirely. This is only feasible when there is some degree of certainty that the tumor can in fact be removed. When it is certain that parts will remain, curative surgery is often impossible, e.g. when there are metastases elsewhere, or when the tumor has invaded a structure that cannot be operated upon without risking the patient's life. Occasionally surgery can improve survival even if not all tumour tissue has been removed; the procedure is referred to as "debulking" (i.e. reducing the overall amount of tumour tissue). Surgery is also used for the palliative treatment of some of cancers, e.g. to relieve biliary obstruction, or to relieve the problems associated with some cerebral tumors. The risks of surgery must be weighed against the benefits.
Chemotherapy and radiotherapy are used as a first-line radical therapy in a number of malignancies. They are also used for adjuvant therapy, i.e. when the macroscopic tumor has already been completely removed surgically but there is a reasonable statistical risk that it will recur. Chemotherapy and radiotherapy are commonly used for palliation, where disease is clearly incurable: in this situation the aim is to improve the quality of life and to prolong it
Hormone manipulation is well established, particularly in the treatment of breast and prostate cancer.
Approximately 50% of all cancer cases in the Western world can be treated to remission with radical treatment. For pediatric patients, that number is much higher. A large number of cancer patients will die from the disease, and a significant proportion of patients with incurable cancer will die of other causes. There may be ongoing issues with symptom control associated with progressive cancer, and also with the treatment of the disease. These problems may include pain, nausea, anorexia, fatigue, immobility, and depression. Not all issues are strictly physical: personal dignity may be affected. Moral and spiritual issues are also important.
While many of these problems fall within the remit of the oncologist, palliative care has matured into a separate, closely allied speciality to address the problems associated with advanced disease. Palliative care is an essential part of the multidisciplinary cancer care team. Palliative care services may be less hospital-based than oncology, with nurses and doctors who are able to visit the patient at home.
There are a number of recurring ethical questions and dilemmas in oncological practice. These include:
- What information to give the patient regarding disease extent/progression/prognosis.
- Entry into clinical trials, especially in the face of terminal illness.
- Withdrawal of active treatment.
- "Do Not Resuscitate" orders and other end of life issues.
These issues are closely related to the patients' personality, religion, culture, and family life. Though these issues are complex and emotional, the answers are often achieved by the patient seeking counsel from trusted personal friends and advisors. It requires a degree of sensitivity and very good communication on the part of the oncology team to address these problems properly.
Progress and research
There is a tremendous amount of research being conducted on all frontiers of oncology, ranging from cancer cell biology, radiation therapy to chemotherapy treatment regimens and optimal palliative care and pain relief. In the past decade, the advent of next-generation sequencing and whole-genome sequencing has completely changed our understanding of cancers. Identification of novel genetic/molecular markers will dramatically change how we diagnose and treat cancer, which will pave the way for personalized medicine.
Therapeutic trials often involve patients from many different hospitals in a particular region. In the UK, patients are often enrolled in large studies coordinated by Cancer Research UK (CRUK), Medical Research Council (MRC), the European Organisation for Research and Treatment of Cancer (EORTC) or the National Cancer Research Network (NCRN).
There are several sub-specialties within oncology. Moreover, oncologists often develop an interest and expertise in the management of particular types of cancer.
Oncologists may be divided on the basis of the type of treatment provided or whether their role is primarily diagnostic.
- Radiology: localize, stage and often perform image-guided biopsy in order to obtain the tissue for preliminary diagnosis.
- Anatomical pathology: render the final diagnosis and prognosis of cancer, in order to guide treatment by oncologists.
- Radiation oncology: treatment primarily with radiation, a process called radiotherapy.
- Surgical oncology: surgeons who specialize in tumor removal.
- Medical oncology: treatment primarily with drugs, that is, pharmacotherapy, which includes chemotherapy, hormonal therapy, and targeted therapy.
- Gynecologic oncology: focuses on cancers of the female reproductive system.
- Pediatric oncology: concerned with the treatment of cancer in children
In the United Kingdom and several other countries, oncologists may be either clinical or medical oncologists. The main difference is that clinical oncologists deliver radiotherapy, while medical oncologists do not. In North America, the terms, radiation oncologist and medical oncologist are more frequent.
In most countries it is now common that patients are treated by a multidisciplinary team. These teams meet on a regular basis and discuss the patients under their care. These teams consist of the medical oncologist, a clinical oncologist or radiotherapist, a surgeon (sometimes there is a second reconstructive surgeon), a radiologist, a pathologist, an organ specific specialist such as a gynecologist or dermatologist, and sometimes the general practitioner is also involved. These disease oriented teams are sometimes in conflict with the general organisation and operation in hospitals. Historically hospitals are organised in an organ or technique specific manner. Multidisciplinary teams operate over these borders and it is sometimes difficult to define who is in charge.
- Experimental cancer treatment
- Fertility preservation
- List of oncology-related terms
- Ocular oncology
- Performance status
- Tumor Bank
- Types of Oncologists, American Society of Clinical Oncology (ASCO).
- National Institute for Health and Clinical Excellence. Clinical guideline 104: Metastatic malignant disease of unknown primary origin: Diagnosis and management of metastatic malignant disease of unknown primary origin. London, 2010.
- Cancer Research UK
- Home - Medical Research Council
- "Types of Oncologists". Cancer.Net : American Society of Clinical Oncology (ASCO). Retrieved 25 May 2013.
- NCI Dictionary of Cancer terms[dead link]
- Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10):703-18.
- Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685-96.
- Katsanis SH, Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet. 2013;14(6):415-26.
- Mardis ER. Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol. 2012;9(8):477-86.
- Siddhartha Mukherjee, The Emperor of All Maladies: A Biography of Cancer, Fourth Estate, 2011 (ISBN 978-0-00-725092-9).
- Vickers, A. (1 March 2004). "Alternative Cancer Cures: "Unproven" or "Disproven"?". CA: A Cancer Journal for Clinicians 54: 110–118. doi:10.3322/canjclin.54.2.110. PMID 15061600.
- Oncology at DMOZ
- Oncowiki: A Wiki based repository of Cancer Chemotherapy Regimens
- European Society for Medical Oncology